Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases

Fineline Cube Nov 29, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...

Company Deals

CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion

Fineline Cube Nov 29, 2024

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics

Fineline Cube Nov 29, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, also recognized as Wuhan...

Company Deals

Shanghai Yanyin Technology Partners with Castalysis Bioscience to Advance CRISPR Software Development

Fineline Cube Nov 29, 2024

Shanghai Yanyin Technology Co., Ltd has announced a strategic partnership with Castalysis Bioscience (Shanghai), a...

Company Drug

Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea

Fineline Cube Nov 29, 2024

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the...

Company

Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation

Fineline Cube Nov 29, 2024

Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator,...

Policy / Regulatory

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition

Fineline Cube Nov 29, 2024

On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...

Company Drug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes

Fineline Cube Nov 28, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...

Company Drug

Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment

Fineline Cube Nov 28, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...

Company Drug

MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study

Fineline Cube Nov 28, 2024

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III...

Policy / Regulatory

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs

Fineline Cube Nov 28, 2024

The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...

Company Deals

Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs

Fineline Cube Nov 28, 2024

Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...

Policy / Regulatory

China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030

Fineline Cube Nov 28, 2024

The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...

Company Drug

Jiangsu Kanion Pharmaceutical Secures NMPA Approvals for KYHY2302 and KYHY2303

Fineline Cube Nov 28, 2024

China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving separate clinical trial approvals...

Policy / Regulatory

NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs

Fineline Cube Nov 28, 2024

The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...

Company Drug

BeiGene’s Tevimbra Receives EC Approval for First-Line ESCC and G/GEJ Adenocarcinoma Treatments

Fineline Cube Nov 28, 2024

China-based biotech company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has received a marketing...

Company Drug

Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders

Fineline Cube Nov 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...

Company Drug

Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE

Fineline Cube Nov 28, 2024

Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...

Company Drug

Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment

Fineline Cube Nov 28, 2024

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...

Company Drug

China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005

Fineline Cube Nov 28, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...

Posts pagination

1 … 212 213 214 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.